Seasonal influenza virus vaccine intranasal - BioDiem
Alternative Names: Influenza vaccine live attenuated - BioDiem; Influenza virus vaccine - BioDiem; Influenza virus vaccine - Serum Institute of India; Influenza virus vaccine live - BioDiem; Influenza virus vaccine live intranasal - BioDiem; LAIV Seasonal intranasal - BioDiem; Live attenuated influenza vaccine - BioDiem; Live attenuated influenza virus vaccine - BioDiem; Nasovac-S; SCH-900795; Seasonal influenza virus vaccine (intranasal) - BioDiem; Seasonal influenza virus vaccine - BioDiem; Trivalent live attenuated seasonal influenza vaccine - Serum Institute of India; Trivalent seasonal influenza virus vaccine - Serum Institute of India/BiodiemLatest Information Update: 05 Nov 2023
At a glance
- Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
- Developer BioDiem; Changchun BCHT Biotechnology; Institute of Experimental Medicine of the Russian Academy of Medical Sciences
- Class Attenuated vaccines; Influenza virus vaccines live; Viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Influenza virus infections
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 17 Mar 2022 Changchun BCHT Biotechnology plans a phase II trial for Influenza virus infections (Prevention, In children, In adolescents, In adults) in China, in April 2022 (Intranasal) (NCT05284851)
- 06 Oct 2021 Changchun BCHT Biotechnology submitted a new drug application (NDA) for Influenza virus infections in 2021 (NCT05056519)
- 19 Feb 2021 BioDiem intends to launch Seasonal influenza virus vaccine intranasal in year 2021